Evogene Ltd.

Report Publication Announcement • May 4, 2023

Evogene Schedules First Quarter 2023 Financial Results Release & Conference Call for May 18, 2023

Conference call scheduled for 9AM ET

Rehovot, Israel – May 4, 2023 – Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN), a leading computational biology company aiming to revolutionize life-science product development, announced today that it will release its financial results for the first quarter of 2023, on Thursday, May 18, 2023.

Later that day, Company management will host a conference call to discuss the results at 9:00AM Eastern time, 4:00PM Israel time.

To access the conference call, please dial +1-888-281-1167 toll free from the United States, or +972-3-918-0609 internationally. Access to the call will also be available via live webcast through the Company's website at www.evogene.com .

A replay of the conference call will be available approximately two hours following the completion of the call. To access the replay, please dial +1-888-326-9310 toll free from the United States, or +972-3-925-5901 internationally. The telephone replay will be accessible for three days, but an archive of the webcast will be available from the webcast link for the following twelve months.

-xxx-

About Evogene:

Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost.

Evogene established three unique tech-engines – MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).

Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:

• 1. Biomica Ltd. (www.biomicamed.com) developing and advancing novel microbiomebased therapeutics to treat human disorders powered by MicroBoost AI;
• 1. Lavie Bio Ltd. (www.lavie-bio.com) developing and commercially advancing, microbiome based ag-biologicals powered by MicroBoost AI;
• 1. AgPlenus Ltd. (www.agplenus.com) developing next generation ag-chemicals for effective and sustainable crop protection powered by ChemPass AI;
• 1. Canonic Ltd. (www.canonicbio.com) developing medical cannabis products based on decoding plant genetics for optimized therapeutic effect powered by GeneRator AI; and
• 1. Casterra Ag Ltd. (www.casterra.co) developing and marketing superior castor seed varieties producing high yield and high-grade oil content, on an industrial scale for the biofuel and other industries powered by GeneRator AI.

For more information, please visit: www.evogene.com.

Investor Contact:

Kenny Green Email: kenny.green@evogene.com Tel: +1 212 378 8040

Rachel Pomerantz Gerber Email: rachel.pomerantz@evogene.com Tel: +972 8 931 1900